Iovance Biotherapeutics Inc (NASDAQ:IOVA) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings estimates for Iovance Biotherapeutics in a note issued to investors on Monday. Jefferies Group analyst B. Amin anticipates that the biotechnology company will post earnings per share of ($0.30) for the quarter. Jefferies Group has a “Buy” rating and a $31.00 price objective on the stock. Jefferies Group also issued estimates for Iovance Biotherapeutics’ Q2 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.31) EPS and FY2022 earnings at $1.60 EPS.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Monday, March 12th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.04).
Shares of Iovance Biotherapeutics (NASDAQ:IOVA) opened at $17.45 on Wednesday. Iovance Biotherapeutics has a 1-year low of $4.45 and a 1-year high of $19.90.
Several institutional investors and hedge funds have recently made changes to their positions in IOVA. New York State Common Retirement Fund purchased a new stake in shares of Iovance Biotherapeutics in the second quarter valued at about $375,000. Northern Trust Corp acquired a new position in Iovance Biotherapeutics in the second quarter valued at about $2,224,000. Vanguard Group Inc. acquired a new position in Iovance Biotherapeutics in the second quarter valued at about $16,113,000. Parametric Portfolio Associates LLC acquired a new position in Iovance Biotherapeutics in the second quarter valued at about $125,000. Finally, Voya Investment Management LLC acquired a new position in Iovance Biotherapeutics in the second quarter valued at about $208,000. 67.82% of the stock is owned by hedge funds and other institutional investors.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.